"Cover all the bases" is the theme of FierceDrugDelivery's annual list of the top drug delivery partnerships. Finding 10 significant alliances that represent the full range of drug delivery advances was a challenge, and there are certainly other deals out there that are both novel and of high importance.
Still, the tie-ups highlighted here represent the arena's diversity on multiple levels. Half of the deals involve use of drug delivery devices like "smart" inhalers and drug-coated angioplasty balloons, while others focus on the molecular aspects, like transportation across biological barriers and the development of formulations that are efficacious and/or differentiate the medication.
We considered deals that commenced in 2014 and so far in 2015.
An innovative clinical trial of previously incarcerated adult schizophrenia patients designed by Johnson & Johnson's Janssen Pharmaceuticals concluded that by improving medication adherence, the company's blockbuster, once-a-month injectable for schizophrenia results in better outcomes than daily oral competitors, as measured by real-world (as opposed to strictly clinical) outcomes like arrest or psychiatric hospitalization. Read more >>
A month after Genmab and Johnson & Johnson's Janssen released successful mid-stage data for its multiple myeloma antibody daratumumab, Halozyme has jumped on board, planning a Phase I trial with its subcutaneous delivery technology. Read more >>
POPULAR COMMENT THREADS
Irish researchers have developed a gel containing clusters of pancreatic cells that they say can control glucose levels for up to 5 years when administered via a minimally invasive injection procedure being developed by medical device bigwig Boston Scientific.
Novartis announced that its investigational combination indacaterol/glycopyrronium bromide therapy for COPD performed better than its constituent components in a Phase III clinical trial.
Companion Medical, a California startup with a Bluetooth-enabled insulin pen and smartphone app, pulled in Series B financing this week, led by Big Pharma player Eli Lilly. Though the amount was undisclosed, the move marks a step forward for Lilly into the world of drug delivery technology, for which the company is currently building an R&D center in Cambridge, MA.
Pacira's liposomal-encased bupivacaine medication was touted at the annual Miami Breast Cancer Conference as an effective postoperative pain reliever following breast removal or reconstruction.
Researchers in Japan have published a study in the journal Science and Technology of Advanced Materials demonstrating greater potential for nanoparticles that can both carry drugs and act as imaging targets to diagnose malignant tumors in the brain.
The FDA gave the green light to Johnson & Johnson's Invega Trinza, which is injected four times a year, making it the longest-acting schizophrenia drug on the market.
From Our Sister Sites
Zimmer will close its Carlsbad, CA, dental headquarters following its looming $13 billion merger with Biomet, resulting an unspecified number of layoffs. The plant closure will occur in 12 months, say internal company emails sent to both companies' employees that were obtained by FierceMedicalDevices.
Johnson & Johnson and AbbVie's Imbruvica has already shown in one Phase III study that it can extend progression-free survival in patients with previously treated chronic lymphocytic leukemia. But now, it's done it again--and convincingly so.